Management of autism in children and young people : a good clinical practice guideline [printed text] / Geneviève Veereman, Author ; Kirsten Holdt Henningsen, Author ; Marijke Eyssen  , Author ; Nadia Benahmed, Author ; Wendy Christiaens , Author ; Marie-Hélène Bouchez, Author ; Ann De Roeck, Author ; Nicolas Deconinck, Author ; Gaby De ligne, Author ; Griet Dewitte, Author ; Tine Gheysen, Author ; Maryse Hendrix, Author ; Claire Kagan, Author ; Ghislain Magerotte, Author ; Marleen Moonen, Author ; Herbert Roeyers, Author ; Sara Schelstraete, Author ; Marie-Vinciane Soncarrieu, Author ; Jean Steyaert, Author ; Flavio Tolfo, Author ; Géraldine Vrancken, Author ; Eric Willaye, Author ; Anne Wintgens, Author ; Sara Wouters, Author ; Jan Croonenberghs, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2014 . - 118 p. : ill., ; A4. - ( KCE Reports. Good Clinical Practice (GCP); 233C) . ISSN : D/2014/10.273/87 : € 0,00 Study n° 2013-22 Languages : English ( eng)
| Descriptors: |
Indexation
2013-22 ; Adolescent ; Child ; Child Development Disorders, Pervasive ; Psychotherapy ; R233 ; Therapeutics
Classification
WS 350.8.P4 Pervasive development disorders
|
| Contents note: |
SCIENTIFIC REPORT 11 -- 1 INTRODUCTION 11 -- 1.1 BACKGROUND 11 -- 1.2 THE NEED FOR A GUIDELINE 12 -- 1.3 SCOPE 12 -- 1.4 REMIT OF THE GUIDELINE 13 -- 1.4.1 Overall objectives 13 -- 1.4.2 Specific aims 13 -- 1.4.3 Target users of the guideline .13 -- 1.5 STATEMENT OF INTENT 13 -- 1.6 FUNDING AND DECLARATION OF INTEREST 14 -- 2 METHODOLOGY 14 -- 2.1 INTRODUCTION 14 -- 2.2 GENERAL APPROACH 14 -- 2.3 THE GUIDELINE DEVELOPMENT GROUP AND THE STAKEHOLDER PANEL 15 -- 2.3.1 The GDG 15 -- 2.3.2 The stakeholders 15 -- 2.4 SEARCH FOR EVIDENCE 16 -- 2.5 QUALITY APPRAISAL 16 -- 2.6 IN- AND EXCLUSION CRITERIA 16 -- 2.7 RESEARCH QUESTIONS 17 -- 2.8 DATA EXTRACTION AND EVIDENCE SUMMARY 19 -- 2.9 FORMULATION OF RECOMMENDATIONS 19 -- 2.10 EXTERNAL REVIEW BY STAKEHOLDERS 20 -- 2.11 FINAL VALIDATION 21 -- 3 DEFINITIONS 21 -- 3.1.1 General definitions 21 -- 3.1.2 Specific interventions 22 -- 4 MANAGEMENT OF CHILDREN AND YOUNG PEOPLE WITH AUTISM 26 -- 4.1 EXPERIENCE OF CARE AND THE ORGANIZATION AND DELIVERY OF CARE 26 -- 4.1.1 NICE 26 -- 4.1.2 HAS guideline 30 -- 4.2 INTERVENTIONS AIMED AT THE CORE FEATURES OF AUTISM 34 -- 4.2.1 Psychosocial interventions for core features of autism 34 -- 4.2.2 Pharmacological interventions for core features of autism 36 -- 4.2.3 Biomedical intervention for core features of autism 37 -- 4.2.4 Recommendations regarding interventions aimed at the core features of autism 38 -- 4.2.5 From evidence to recommendations 47 -- 4.3 INTERVENTIONS AIMED AT BEHAVIOUR THAT CHALLENGES 47 -- 4.3.1 Evidence – psychosocial interventions 48 -- 4.3.2 Effect of psychosocial interventions on behaviour that challenges 48 -- 4.3.3 Evidence - pharmacological interventions 48 -- 4.3.4 Effect of pharmacological interventions on behaviour that challenges 48 -- 4.3.5 Evidence – biomedical interventions 49 -- 4.3.6 Effect of biomedical interventions on behaviour that challenges 49 -- 4.3.7 From evidence to recommendations 54 -- 4.4 INTERVENTIONS AIMED AT ASSOCIATED FEATURES OF AUTISM AND COEXISTING CONDITIONS 54 -- 4.4.1 Impairments in adaptive behaviour 54 -- 4.4.2 Speech and language problems 58 -- 4.4.3 IQ, academic skills and learning 64 -- 4.4.4 Sensory sensitivities 68 -- 4.4.5 Motor difficulties 71 -- 4.4.6 Common coexisting mental health problems 74 -- 4.4.7 Common medical and functional problems 78 -- 4.4.8 Specific interventions related to sexuality for adolescents 86 -- 4.4.9 From evidence to recommendations 87 -- 4.5 INTERVENTIONS AIMED AT IMPROVING THE IMPACT ON THE FAMILY 87 -- 4.5.1 Psychosocial interventions aimed at improving the impact of autism on the family 87 -- 4.5.2 Pharmacological interventions aimed at improving the impact of autism on the family 87 -- 4.5.3 Biomedical interventions aimed at improving the impact of autism on the family 88 -- 4.5.4 From evidence to recommendations 90 -- 4.6 ADVERSE EVENTS ASSOCIATED WITH INTERVENTIONS 90 -- 4.6.1 Harms associated with psychosocial interventions 90 -- 4.6.2 Harms associated with pharmacological interventions. 90 -- 4.6.3 Harms associated with biomedical interventions 93 -- 4.6.4 Conclusion regarding adverse events associated with interventions 93 -- 4.6.5 From evidence to recommendations 94 -- 5 RECOMMENDATIONS 94 -- 5.1 RECOMMENDATIONS ADAPTED BY GDG FROM THE NICE AND HAS GUIDELINE 94 -- 5.1.1 Other considerations 105 -- 5.2 GLOBAL SUMMARY OF RECOMMENDATIONS 105 -- 5.3 RECOMMENDATIONS FOR FURTHER RESEARCH 107 -- 5.3.1 Other considerations 108 -- 5.3.2 Perspectives 108 -- 6 CONSENSUS STATEMENT APPLIED TO THE BELGIAN CONTEXT 109 -- 6.1 INTRODUCTION 109 -- 6.2 ORGANIZATION OF CARE AND EDUCATION IN BELGIUM 110 -- 6.3 DOCUMENTS AND WEBSITES RELATED TO AUTISM IN CHILDREN AND ADOLESCENTS 110 -- 6.3.1 Advice of the Belgian National Superior Health Council 111 -- 6.4 OPINION ON PRIORITIES TO IMPROVE THE CARE FOR CHILDREN AND ADOLESCENTS WITH -- AUTISM IN BELGIUM 111 -- 6.4.1 Other considerations 113 -- 6.5 CONCLUSIONS 113 -- 7 IMPLEMENTATION AND UPDATING OF THE GUIDELINE 113 -- 7.1 IMPLEMENTATION 113 -- 7.1.1 Barriers and facilitators for implementation of this guideline 113 -- 7.2 GUIDELINE UPDATE 114 -- REFERENCES 115 |
| Link for e-copy: |
https://doi.org/10.57598/R233C |
| Format of e-copy: |
PDF (2,71 Mb) |
| Record link: |
https://kce.docressources.info/index.php?lvl=notice_display&id=3465 |
|  |
Add the result to your basket Make a suggestion Refine your search Apply to external sourcesJaarverslag 2021 / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2022)
Multidisciplinary outpatient rehabilitation following cardiac revascularization or valve surgery in European Journal of Preventive Cardiology, 20(2013)03 ([06/01/2013])
"More about author"